Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

680 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial.
Yamamoto K, Natsuaki M, Watanabe H, Morimoto T, Obayashi Y, Nishikawa R, Ando K, Suwa S, Isawa T, Takenaka H, Ishikawa T, Ikari Y, Kurita T, Kaitani K, Sugimoto A, Ogata N, Ikuta A, Hashimoto K, Ishibashi Y, Masuda K, Miyabe T, Ono K, Kimura T. Yamamoto K, et al. Among authors: ogata n. Eur Heart J Cardiovasc Pharmacother. 2024 Oct 23:pvae075. doi: 10.1093/ehjcvp/pvae075. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 39444052
Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial.
Obayashi Y, Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Nishikawa R, Ando K, Suwa S, Isawa T, Takenaka H, Ishikawa T, Tokuyama H, Sakamoto H, Fujita T, Nanasato M, Okayama H, Nishikura T, Kirigaya H, Nishida K, Ono K, Kimura T; STOPDAPT-3 investigators. Obayashi Y, et al. Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):374-390. doi: 10.1093/ehjcvp/pvae009. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38285607 Clinical Trial.
An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention.
Yamamoto K, Natsuaki M, Watanabe H, Morimoto T, Obayashi Y, Nishikawa R, Ando K, Suwa S, Isawa T, Takenaka H, Ishikawa T, Tamura T, Kawahatsu K, Hayashi F, Akao M, Serikawa T, Mori H, Kawamura T, Hagikura A, Shibata N, Ono K, Kimura T; STOPDAPT-3 Investigators. Yamamoto K, et al. JACC Cardiovasc Interv. 2024 May 13;17(9):1119-1130. doi: 10.1016/j.jcin.2024.03.017. JACC Cardiovasc Interv. 2024. PMID: 38749592
Initial results of transradial iliac artery stenting.
Shinozaki N, Ogata N, Ikari Y. Shinozaki N, et al. Among authors: ogata n. Vasc Endovascular Surg. 2014 Jan;48(1):51-4. doi: 10.1177/1538574413510621. Epub 2013 Nov 6. Vasc Endovascular Surg. 2014. PMID: 24203346
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial.
Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T; NEXT Investigators. Natsuaki M, et al. Among authors: ogata n. J Am Coll Cardiol. 2013 Jul 16;62(3):181-190. doi: 10.1016/j.jacc.2013.04.045. Epub 2013 May 15. J Am Coll Cardiol. 2013. PMID: 23684673 Free article. Clinical Trial.
Potential difficulty for accurate categorization of drug-eluting stent thrombosis without coronary angiography: unignorable involvement of the cases with new onset acute myocardial infarction occurred in target vessels.
Fujii T, Morino Y, Ito D, Shima M, Tamiya S, Toda E, Sugimoto A, Masuda N, Matsukage T, Ogata N, Tanabe T, Ikari Y. Fujii T, et al. Among authors: ogata n. Cardiovasc Interv Ther. 2011 May;26(2):109-16. doi: 10.1007/s12928-011-0048-1. Epub 2011 Feb 3. Cardiovasc Interv Ther. 2011. PMID: 24122531
Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T. Natsuaki M, et al. Among authors: ogata n. Circ Cardiovasc Interv. 2015 Oct;8(10):e002817. doi: 10.1161/CIRCINTERVENTIONS.115.002817. Circ Cardiovasc Interv. 2015. PMID: 26446596 Clinical Trial.
680 results